First Time Loading...

Guangdong Hybribio Biotech Co Ltd
SZSE:300639

Watchlist Manager
Guangdong Hybribio Biotech Co Ltd Logo
Guangdong Hybribio Biotech Co Ltd
SZSE:300639
Watchlist
Price: 6.07 CNY -2.57% Market Closed
Updated: May 15, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Guangdong Hybribio Biotech Co Ltd

Wall Street analysts forecast Guangdong Hybribio Biotech Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Guangdong Hybribio Biotech Co Ltd is 40.09 CNY .

Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
40.09 CNY
560% Upside
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
40.09 CNY
560% Upside
Highest
Price Target
Not Available
Guangdong Hybribio Biotech Co Ltd Competitors:
Price Targets
RXRX
Recursion Pharmaceuticals Inc
33% Upside
ATORX
Alligator Bioscience AB
153% Upside
ABBV
Abbvie Inc
14% Upside
BIOG B
Biogaia AB
17% Upside
RXRX
Recursion Pharmaceuticals Inc
33% Upside
ATORX
Alligator Bioscience AB
153% Upside
ABBV
Abbvie Inc
14% Upside
BIOG B
Biogaia AB
17% Upside
APLT
Applied Therapeutics Inc
164% Upside
300896
Imeik Technology Development Co Ltd
61% Upside
NTLA
Intellia Therapeutics Inc
178% Upside
OVID
Ovid Therapeutics Inc
131% Upside

Revenue
Forecast

Revenue Estimate
Guangdong Hybribio Biotech Co Ltd

For the last 8 years the compound annual growth rate for Guangdong Hybribio Biotech Co Ltd's revenue is 16%. The projected CAGR for the next 2 years is 38%.

16%
Past Growth
38%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Guangdong Hybribio Biotech Co Ltd

Operating Income forecast
is not available for
Guangdong Hybribio Biotech Co Ltd

Net Income
Forecast

Net Income Estimate
Guangdong Hybribio Biotech Co Ltd

For the last 8 years the compound annual growth rate for Guangdong Hybribio Biotech Co Ltd's net income is 10%. The projected CAGR for the next 2 years is 61%.

10%
Past Growth
61%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Guangdong Hybribio Biotech Co Ltd's stock price target?
Price Target
40.09 CNY

According to Wall Street analysts, the average 1-year price target for Guangdong Hybribio Biotech Co Ltd is 40.09 CNY .

What is Guangdong Hybribio Biotech Co Ltd's Revenue forecast?
Projected CAGR
38%

For the last 8 years the compound annual growth rate for Guangdong Hybribio Biotech Co Ltd's revenue is 16%. The projected CAGR for the next 2 years is 38%.

What is Guangdong Hybribio Biotech Co Ltd's Net Income forecast?
Projected CAGR
61%

For the last 8 years the compound annual growth rate for Guangdong Hybribio Biotech Co Ltd's net income is 10%. The projected CAGR for the next 2 years is 61%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.